Far red and near infrared light-mediated conditioning of tissues and/or blood to prevent reperfusion injury in endovascular therapies
Inventors
Lohr, Nicole • Salinger, Michael
Assignees
Publication Number
US-11998757-B2
Publication Date
2024-06-04
Expiration Date
2042-03-22
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Reperfusion injury is limited during endovascular therapies (e.g., revascularization and/or reperfusion of end organ tissues) by conditioning the tissues against reperfusion injury using an optical fiber catheter to deliver far red and near infrared (R/NIR) light to the tissues. The light may be multiple wavelength or single wavelength light, and may have one or more wavelengths selected from the range of 510 to 830 nm. The R/NIR light may be delivered concurrently with the endovascular therapy, or in other instances may be delivered before or after a particular therapy.
Core Innovation
The invention provides a method for conditioning tissues or blood to reduce reperfusion injury during endovascular therapies, such as revascularization or reperfusion of end organ tissues. This is achieved by delivering far red and near infrared (R/NIR) light, using an optical fiber catheter or a transdermal light delivery system, to the targeted tissues or blood. The R/NIR light can be of single or multiple wavelengths, specifically within the 510 to 830 nm range, and can be administered before, during, or after the endovascular therapy.
The problem addressed is the occurrence of reperfusion injury following procedures that restore blood flow, such as myocardial reperfusion used to treat heart attacks (ST-elevation myocardial infarction, STEMI). Existing therapies do not effectively condition myocardial tissues to prevent or reduce reperfusion injuries. The disclosed approach introduces a method and system to condition tissues by light delivery, aiming to mitigate these injuries.
The innovation allows for precise delivery of R/NIR light to various tissues (including heart, brain, kidney, and extremities), using controlled optical parameters such as wavelength, output fluence, pulse mode, and timing relative to the vascular procedure. The system may include an optical fiber catheter introduced into the vasculature or a transdermal system applied to the skin surface, both controlled for duration, intensity, and wavelength to optimize the conditioning effect and limit reperfusion injury.
Claims Coverage
There are two independent claims, each covering a method for conditioning tissues or blood to reduce reperfusion injury via light delivery using either an optical fiber catheter or a transdermal light source in conjunction with endovascular therapy.
Conditioning tissues or blood with optical fiber catheter-delivered light to reduce reperfusion injury
- Providing an optical fiber catheter to a region in a subject containing tissues or blood. - Operating a light source coupled to the proximal end of the catheter to generate light with at least one wavelength from 510 nm to 670 nm, emitting this light at the distal tip to impinge on the tissues or blood. - Administering an endovascular therapy to the tissues or blood in that region. - Achieving significant reduction of reperfusion injury in the tissues or blood as a result of the emitted light conditioning.
Conditioning tissues or blood with transdermal light source to reduce reperfusion injury
- Providing a transdermal light source to the skin surface of a subject. - Operating the transdermal light source to generate and emit light having at least one wavelength from 510 nm to 670 nm to impinge on tissues or blood in a subdermal region. - Administering an endovascular therapy to the tissues or blood in that region. - Achieving significant reduction of reperfusion injury in the subdermal tissues as a result of the conditioning by the emitted light.
The inventive features cover methods for reducing reperfusion injury through precisely delivered R/NIR light, either by internal optical fiber catheterization or by non-invasive transdermal application, both in conjunction with endovascular therapies.
Stated Advantages
Enables limitation of reperfusion injury during endovascular therapies by conditioning tissues with far red and near infrared light.
Allows conditioning of tissues against reperfusion injury without the need for exogenous sodium nitrite or other pharmacological agents.
Facilitates nitric oxide generation and tissue salvage via NO-dependent pathways during endovascular therapy.
Supports both optical fiber catheter-based and transdermal light delivery, expanding its applicability across different clinical scenarios.
Documented Applications
Transcatheter reperfusion of acute myocardial infarction (MI), including during percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) and acute coronary ischemia (ACS).
Transcatheter reperfusion of ischemic stroke and traumatic brain injury to limit cerebral injury and improve brain salvage.
Transcatheter reperfusion of the kidneys to limit renal injury during percutaneous renal artery interventions.
Transcatheter revascularization of ischemic limbs to limit reperfusion injury and improve responses to peripheral intra-arterial interventions, such as limb salvage and wound healing.
Use in conjunction with excimer laser systems for protective conditioning of tissues before, during, or after plaque ablation procedures.
Combination with transcatheter supersaturated oxygen (SSO2) delivery systems to limit infarct size and improve myocardial salvage.
Interested in licensing this patent?